Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Desmopressin · 1 trial · 1 indication
Bioequivalence based on Cmax
Bioequivalence based on AUCinf
Bioequivalence based on AUC0-t
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | - |
| 2 | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Desmopressin Acetate 0.2 mg Tablets | DRUG | 4 x 0.2 mg, single-dose fasting |
| DDAVP® 0.2 mg Tablets | DRUG | 4 x 0.2 mg, single-dose fasting |
Inclusion Criteria: * Healthy adult non-smoker (for at least 3 months) or light smoking (less than 10 cigarettes per day for at least 3 months) male or female subjects, 18-55 years of age; * Weighing at least 60 kg for males and 52 kg for females; * Subjects who had a body mass index (BMI) less tha...
Desmopressin is a small molecule being developed by Teva Pharmaceutical Industries Limited. It is currently in Phase 1 clinical trials for use in healthy volunteers. The drug is being studied as an active-controlled treatment, with one completed trial involving 48 participants.
Desmopressin is being developed by Teva Pharmaceutical Industries Limited, a company traded under the ticker TEVA. The drug is currently in Phase 1 clinical development, with one completed trial in healthy volunteers.
Desmopressin is in Phase 1 clinical development. It has one completed trial, NCT00835211, which was a Phase 1 study in healthy volunteers. The drug is investigational and has not been approved for any indication.
Desmopressin has one clinical trial, NCT00835211, titled 'Desmopressin Acetate 0.2 mg Tablets, Fasting'. This Phase 1 study was completed and enrolled 48 healthy volunteers in Canada, with participants aged 18 years and older.
Desmopressin is not FDA approved. It is an investigational drug currently in Phase 1 clinical development. The only trial for this drug, NCT00835211, has been completed, but approval status has not been established.